| Entry |
|
|---|
| Name |
Ertugliflozin and sitagliptin;
Steglujan (TN)
|
|---|
| Product |
|
|---|
| Component |
(Ertugliflozin pidolate [DR: D11043] | Ertugliflozin [DR: D10313]), (Sitagliptin phosphate [DR: D06645] | Sitagliptin [DR: D08516])
|
|---|
| Remark |
|
|---|
| Efficacy |
Antidiabetic |
|---|
| Disease |
Type 2 diabetes mellitus [DS: H00409] |
|---|
| Comment |
Ertugliflozin is primarily metabolized by UGT1A9 and UGT2B7.
|
|---|
| Metabolism |
Enzyme: UGT1A9 [HSA: 54600], UGT2B7 [HSA: 7364]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BD Combinations of oral blood glucose lowering drugs
A10BD24 Sitagliptin and ertugliflozin
D11066 Ertugliflozin and sitagliptin <US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Combinations
Ertugliflozin/ Sitagliptin
D11066 Ertugliflozin and sitagliptin
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11066
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11066
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
